Mercator Medical flags softer production results: PLN 539.5 million values Mercator Medical stock

Published on 10/20/2026 at 12:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 EBITDA was PLN 61.4 million versus a PLN 0.7 million loss. Mercator Medical stock is EUR 13.48 on October 20, 2026, at PLN 539.5 million.

Margins and production costs

Mercator Medical reported PLN 61.4 million in first-half 2026 EBITDA on October 1, 2026.
Nitryl costs had risen more than 25 percent by October 6, 2026, putting pressure on production margins.
Mercator Medical stock trades at EUR 13.48 at 12:37 p.m. CEST at Lang & Schwarz on October 20, 2026.

Mercator Medical, PLMRCTR00015, Illustration mit AI erstellt.

Mercator Medical (ISIN PLMRCTR00015) had flagged softer production-segment results as nitryl costs rose more than 25 percent, while its stock stood at EUR 13.48 at Lang & Schwarz on October 20, 2026, at 12:37 p.m. CEST. The warning followed a sharp improvement in first-half earnings and gave investors a clear counterweight to the stronger results.

Production costs test the recovery

On October 6, 2026, Mercator Medical President Monika Zyznowska said the production segment could deliver slightly lower results in subsequent quarters because nitryl costs had risen more than 25 percent compared with the first half. According to Strefa Inwestorow, demand for gloves was stabilizing, while higher selling prices had supported first-half revenue and earnings.

The cost issue matters because the first-half recovery was driven by wider margins, a better sales mix and improved purchasing conditions. The company said its operating plans remained unchanged, with product diversification, automation and broader supply sources aimed at containing pressure on the manufacturing business.

What do the results mean for margins?

Mercator Medical reported PLN 337.2 million in consolidated sales revenue for the first half of 2026, up 16 percent year over year. EBITDA reached PLN 61.4 million, compared with negative EBITDA of PLN 0.7 million in the first half of 2025, while net profit rose 170 percent to PLN 57.7 million.

Sales in the United States reached PLN 136.8 million in the first half of 2026, up 29.3 percent year over year and representing 40.6 percent of group sales. That growth provides support for the distribution business, but the next results will show whether higher raw-material costs absorb part of the manufacturing improvement.

Three dates frame the recovery

On June 30, 2026, the annual meeting approved a gross dividend of PLN 1.64 per share, paid in August. On September 30, 2026, the company published its first-half report, showing PLN 337.2 million in sales and PLN 57.7 million in net profit. On October 6, 2026, management said higher nitryl costs could make production results slightly lower in subsequent quarters.

When are the next milestones?

The next scheduled reporting date is November 30, 2026, when Mercator Medical plans to publish its consolidated third-quarter 2026 report, according to the company's investor calendar. The dividend payment date was August 5, 2026, making the November report the next dated operating milestone.

Stock price and market value

Mercator Medical stock was trading at EUR 13.48 at Lang & Schwarz on October 20, 2026, at 12:37 p.m. CEST. The Warsaw-listed company had a market capitalization of PLN 539.5 million, with a 52-week range of PLN 37.00 to PLN 63.70 on October 20, 2026. The further course of trading is shown by the continuously updated real-time quote of Mercator Medical stock.